Table 1.

Relevant patient characteristics by dosage group

BSE-SFN dosage group
50 μmol (n = 6)100 μmol (n = 6)200 μmol (n = 5)
Sex (female)3 (50%)4 (67%)5 (100%)
Age (median)46 yrs.51 yrs.44 yrs.
Race (Caucasian)6 (100%)6 (100%)5 (100%)
Prior melanoma history, by stageMIS (1)MIS (1)Stage I (4)
Stage I (4)Stage I (3)Stage III (1)
Stage II (2)Stage III (1) unstageable (1)
  • Abbreviation: MIS, melanoma in situ.